Collaborator of Aravax, the Benaroya Research Institute, receives $5 million National Institute of H
29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute of Health funding to support investigations into the immune mechanisms of PVX108. The research group led by Erik Wambre (PhD) from the Benaroya Research Institute, became a collaborator of the Australian Biotechnology company Aravax in January 2017. The goal of this funding is to accelerate discovery of treatments for peanut allergies through a collaborative, two-pronged project. The first part of the project aims to better understand and characterise the immune response to peanut in peanut allergic patients. The second part of the project will evaluate
Aravax presents encouraging preliminary Phase I safety data at the worlds’ first Gordon Research Con
13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the first Phase I clinical trial of its product known as PVX108 at the Gordon Research Conference on Food Allergy at Ventura Beach in California, held from the 7th-12th January 2018. The Gordon Research Conference brought together leading researchers, clinicians, regulatory and industry representatives from around the world who are working towards revolutionising the standard of clinical care for sufferers of food allergies. Aravax’s Phase I clinical trial AVX-001 is a two stage, randomised, double blind, placebo-controlled study to evaluate the safety and tolera
9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy treatment, today held the first meeting of its newly appointed Scientific Advisory Board, at the Gordon’s Research Conference on Food Allergy at Ventura Beach in California. Aravax is delighted to welcome 5 members to the Scientific Advisory Board. Mark Larché, PhD, is Professor of Medicine at McMaster University, Canada. He is also Chair in Lung Immunology at St. Joseph’s Healthcare, and the Canada Research Chair in Allergy & Immune Tolerance. Professor Larché brings world leading expertise in translational medicine and the development of peptide-based va